Levi & Korsinsky LLP
12/04/2025 | Press release | Distributed by Public on 12/04/2025 08:06
Telix Faces Securities Lawsuit for Allegedly Misleading Investors
Telix promised a future full of growth. New cancer drugs. A global rollout. A rock-solid supply chain. Investors were excited. Everything looked set for a major leap.
But the story behind the scenes was very different.
In February 2025, Telix told investors its prostate cancer program was thriving and its manufacturing partners were ready to scale. In July, that confidence cracked. The company revealed the SEC had issued a subpoena over its prostate cancer disclosures. Shares dropped about 15%.
Then came August 2025. The FDA sent Telix a harsh letter, citing manufacturing problems and deficiencies at two of Telix's partners. The stock fell another 16% in a single day. Investors were stunned. Trust evaporated.
Now, more investors are joining the lawsuit.
Levi & Korsinsky LLP published this content on December 04, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 04, 2025 at 14:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]